TuHURA Biosciences Inc (HURA) Income Statement
HURA FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsHURA revenue and net income
HURA growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HURA quarterly EPS vs estimates
TuHURA Biosciences beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.14).
HURA income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $116,710 | $55,000 | $60,000 | $60,000 | $32,000 | $10,000 | $16,348 | $24,528 | $16,683 |
| Gross profit | — | −$116,710 | −$55,000 | −$60,000 | −$60,000 | −$32,000 | −$10,000 | −$16,348 | −$24,528 | −$16,683 |
| Research & development | $20.5M | $13.3M | $2.7M | $9.3M | $15.2M | $11.8M | $3.6M | $3.7M | $7.1M | $5.0M |
| Sales, general & admin | $7.6M | $3.9M | $4.1M | $2.0M | $2.4M | — | — | — | — | — |
| Total operating expenses | $31.8M | $17.6M | $8.4M | $14.7M | $22.6M | $21.5M | $8.1M | $8.4M | $11.2M | $8.3M |
| Operating income | −$31.8M | −$17.6M | −$8.5M | −$14.8M | −$22.7M | −$21.6M | −$8.1M | −$8.4M | −$11.2M | −$8.3M |
| Interest income | $136,233 | $361,632 | $89,673 | $57,351 | $0 | — | — | — | — | — |
| Interest expense | $625,283 | $4.1M | $18,688 | $0 | $629,286 | $120,000 | — | — | — | — |
| Income before taxes | −$30.1M | −$21.7M | −$8.3M | −$14.6M | −$22.7M | −$38.3M | −$9.1M | −$8.0M | −$11.1M | −$8.1M |
| Income taxes | — | — | −$1 | — | — | — | — | — | — | — |
| Net income | −$30.1M | −$21.7M | −$8.3M | −$14.6M | −$22.7M | −$38.3M | −$9.1M | −$8.0M | −$11.1M | −$8.1M |
| EBITDA | −$29.4M | −$17.4M | −$8.1M | −$14.3M | −$22.0M | −$38.1M | −$9.1M | −$8.0M | −$11.1M | −$8.1M |
| EPS (diluted) | −$0.57 | −$77.26 | −$0.20 | −$75.79 | −$0.52 | −$1.99 | −$0.87 | −$3.20 | −$7877.33 | −$12934.24 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $23,472 | — | $21,000 | — | $14,058 | $17,635 | $29,000 | $17,000 | $34,307 | $15,000 | $15,000 |
| Gross profit | — | −$23,472 | — | −$21,000 | — | −$14,058 | −$17,635 | −$29,000 | −$17,000 | −$34,307 | −$15,000 | −$15,000 |
| Research & development | $6.6M | $5.2M | $6.1M | $5.0M | $4.9M | $4.6M | $4.0M | $2.9M | $101,000 | $3.6M | $111,000 | $1.9M |
| Sales, general & admin | $2.1M | $2.3M | $1.6M | $1.8M | $1.0M | $2.0M | — | $2.0M | $795,660 | $1.0M | — | $1,098 |
| Total operating expenses | $8.8M | $7.5M | $8.2M | $6.7M | $9.9M | $7.0M | $5.7M | $3.7M | $2.4M | $4.6M | $1.0M | $2.9M |
| Operating income | −$8.8M | −$7.5M | −$8.2M | −$6.7M | −$9.9M | −$7.0M | −$5.7M | −$3.7M | −$2.4M | −$4.6M | −$1.0M | −$3.0M |
| Interest income | $7,620 | $21,275 | $609 | $6,060 | $29,466 | $100,098 | — | — | $58,040 | $6,642 | — | — |
| Interest expense | $467,634 | $27,974 | $608,751 | $16,532 | $0 | $0 | $522,835 | $2.0M | $1.4M | $255,122 | — | — |
| Income before taxes | −$9.2M | −$7.5M | −$6.8M | −$7.1M | −$9.5M | −$6.7M | −$6.0M | −$5.6M | −$2.3M | −$4.8M | −$1.0M | −$3.0M |
| Net income | −$9.2M | −$7.5M | −$6.8M | −$7.1M | −$9.5M | −$6.7M | −$6.0M | −$5.6M | −$2.3M | −$4.8M | −$1.0M | −$3.0M |
| EBITDA | −$8.7M | −$7.5M | −$6.1M | −$7.1M | −$9.5M | −$6.7M | −$5.5M | −$3.5M | −$2.3M | −$4.6M | −$1.0M | −$2.9M |
| EPS (diluted) | −$0.14 | −$0.13 | −$0.16 | −$0.14 | −$0.21 | −$0.15 | −$0.14 | −$3.00 | — | −$1.58 | −$8.27 | −$63.91 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HURA's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HURA financial results
TuHURA Biosciences reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $30.1 million. Diluted earnings per share came to −$0.57.
See the HURA stock overview for the latest quote and news, or the HURA chart for price history and technical indicators.
HURA income statement FAQ
Does TuHURA Biosciences have revenue?
TuHURA Biosciences reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is TuHURA Biosciences profitable?
No. TuHURA Biosciences reported a net loss of $30.1 million in fiscal 2026.
How much does TuHURA Biosciences spend on research and development?
TuHURA Biosciences spent $20.5 million on research and development in fiscal 2026.
What are TuHURA Biosciences's earnings per share?
TuHURA Biosciences earned $-0.57 per diluted share in fiscal 2026, compared with $-77.26 a year earlier.
When will TuHURA Biosciences report its next earnings?
TuHURA Biosciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 before the market opens.
When does TuHURA Biosciences's fiscal year end?
TuHURA Biosciences's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on March 31, 2026.